Abstract
Purpose
The purpose of this study was to develop a simple prognostic model based on objective indicators alone, i.e., routine blood test data, without using any subjective variables such as patient’s symptoms and physician’s prediction.
Methods
The subjects of this retrospective study were patients at the palliative care unit of Tohoku University Hospital, Japan. Eligible patients were over 20 years old and had advanced cancer (n = 225). The model for predicting survival was developed based on Cox proportional hazards regression models for univariable and multivariable analyses of 20 items selected from routine blood test data. All the analyses were performed according to the TRIPOD statement (https://www.tripod-statement.org/).
Results
The univariable and multivariable regression analyses identified total bilirubin, creatinine, urea/creatinine ratio, aspartate aminotransferase, albumin, total leukocyte count, differential lymphocyte count, and platelet/lymphocyte ratio as significant risk factors for mortality. Based on the hazard ratios, the area under the curve for the new risk model was 0.87 for accuracy, 0.83 for sensitivity, and 0.74 for specificity. Diagnostic accuracy was higher than provided by the Palliative Prognostic Score and the Palliative Prognostic Index. The Kaplan–Meier analysis demonstrated a survival significance of classifying patients according to their score into low-, medium-, and high-mortality risk groups having median survival times of 67 days, 34 days, and 11 days, respectively (p < 0.001).
Conclusions
We developed a simple and accurate prognostic model for predicting the survival of patients with advanced cancer based on routine blood test values alone that may be useful for appropriate advanced care planning in a palliative care setting.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The authors have full control of all primary data and the journal may review the data if requested.
References
Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, Christakis N (2003) A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ 327:195–198
Maltoni M, Caraceni A, Brunelli C, Croeckaert B, Christakis N, Eychmuller S et al (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248
Stone PC, Lund S (2007) Predicting prognosis in patients with advanced cancer. Ann Oncol 18:971–976
Morita T, Tsunoda J, Inoue S, Chihara S (1999) The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7:128–133
Maltoni M, Nanni O, Pirovano M, Scarpi E, Indelli M, Martini C et al (1999) Successful validation of the Palliative Prognostic Score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care J Pain Symptom Manage 17:240–247
Gwilliam B, Keeley V, Todd C, Gittins M, Roberts C, Kelly L, et al. (2111) Development of Prognosis in Palliative Care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ 343:d4920
Hui D, Park M, Liu D, Palva CF, Suh S-Y, Morita T et al (2016) Clinician prediction of survival versus the Palliative Prognostic Score: which approach is more accurate? Eur J Cancer 64:89–95
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DSJ, Foulis AK et al (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumor site: a Glasgow Inflammation Outcome Study. Br J Cancer 104:726–734
Chen Y-T, Ho C-T, Hsu H-S, Huang P-T, Lin C-Y, Liu C-S, Li TC, Lin CC, Lin WY (2015) Objective palliative prognostic score among patients with advanced cancer. J Pain Symptom Manag 49:690–696
Hamano J, Takauchi A, Yamaguchi T, Baba M, Imai K, Ikenaga M et al (2018) A combination of routine laboratory findings and vital signs can predict survival of advanced cancer patients without physician evaluation: a fractional polynomial model. Eur J Cancer 105:50–60
Okugawa Y, Shirai Y, Nodono H, Matsutani F, Itoh M, Hishida A et al (2017) Objective predictive score as a feasible biomarker for short-term survival in terminally ill patients with cancer. Anticancer Res 37:267–276
Niki K, Okamoto Y, Tabata Y, Tsugane M, Murata T, Mizuki M, Matsumura Y, Takagi T, Uejima E (2018) A new approach for determining short-term, objective prognostic predictive methods for terminal cancer patients based on the change point of laboratory test values. J Palliat Med 21:529–532
Reid VL, MacDonald R, Nwosu AC, Mason SR, Probert C, Ellershaw JE et al (2017) A systematically structured review of biomarkers of dying in cancer patients in the last months of life: an exploration of the biology of dying. PLoS One 12:e0175123
Simmons CPL, McMillan DC, McWilliams K, Sande TA, Fearon KC, Tuck S et al (2017) Prognostic tools in patients with advanced cancer: a systematic review. J Pain Symptom Manag 53:962–970
Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ et al (2005) Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181–184
Hu P, Shen H, Wang G, Zhang P, Liu Q, Du J (2014) Prognostic significance of systemic inflammation-based lymphocyte–monocyte ratio in patients with lung cancer: based on a large cohort study. PLoS One 9:e108062
Hang J, Xue P, Yang H, Li S, Chen D, Zhu L, Huang W, Ren S, Zhu Y, Wang L (2017) Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Sci Rep 7:2993
Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472
Lemon SC, Roy J, Clark MA, Friedmann PD, Rakowski W (2003) Classification and regression tree analysis in public health: methodological review and comparison with logistic regression. Ann Behav Med 26:172–181
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
Roxburgh CSD, McMillan DC (2014) Cancer and systematic inflammation: treat the tumor and treat the host. Br J Cancer 110:1409–1412
Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69
Ding N, Pang Z, Shen H, Ni Y, Du J, Liu Q (2016) The prognostic value of PLR in lung cancer: a meta-analysis based on results from a large consecutive cohort. Sci Rep 26:34823
Amano K, Maeda I, Morita T, Baba M, Miura T, Hama T et al (2017) C-reactive protein, symptoms and activity of daily life living in patients with advanced cancer receiving palliative care. J Cachexia Sarcopenia Muscle 8:457–465
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The protocol of this study was in accordance with the ethical guidelines of the Helsinki declaration and was approved by the ethics committee of the Tohoku University Graduate School of Medicine (reference no. 2019-1-281).
Conflict of interest
The authors declare that they have no conflict of interest.
Consent to participate and consent for publication
All authors reviewed and approved the final draft of the manuscript and approved its publication.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Miyagi, T., Miyata, S., Tagami, K. et al. Prognostic model for patients with advanced cancer using a combination of routine blood test values. Support Care Cancer 29, 4431–4437 (2021). https://doi.org/10.1007/s00520-020-05937-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-020-05937-5